Sonal Singh to Thiazolidinediones
This is a "connection" page, showing publications Sonal Singh has written about Thiazolidinediones.
Connection Strength
2.961
-
Singh S, Suchard MA. Pioglitazone Use and Risk of Bladder Cancer. JAMA. 2015 Dec 15; 314(23):2567-8.
Score: 0.500
-
Singh S, Segal JB. Thiazolidinediones and macular edema: comment on "Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes". Arch Intern Med. 2012 Jul 09; 172(13):1011-3.
Score: 0.394
-
Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ. 2011 Mar 17; 342:d1309.
Score: 0.359
-
Singh S, Loke YK, Furberg CD. Long-term use of thiazolidinediones and the associated risk of pneumonia or lower respiratory tract infection: systematic review and meta-analysis. Thorax. 2011 May; 66(5):383-8.
Score: 0.357
-
Singh S, Loke YK. The safety of rosiglitazone in the treatment of type 2 diabetes. Expert Opin Drug Saf. 2008 Sep; 7(5):579-85.
Score: 0.301
-
Singh S, Furberg CD. Thiazolidinediones and cardiovascular outcomes in type 2 diabetes. Heart. 2009 Jan; 95(1):1-3.
Score: 0.301
-
Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007 Sep 12; 298(10):1189-95.
Score: 0.282
-
Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care. 2007 Aug; 30(8):2148-53.
Score: 0.276
-
Turner RM, Kwok CS, Chen-Turner C, Maduakor CA, Singh S, Loke YK. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. Br J Clin Pharmacol. 2014 Aug; 78(2):258-73.
Score: 0.114
-
Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009 Jan 06; 180(1):32-9.
Score: 0.077